Sun Pharma
平静India's largest and world's fifth-largest specialty generics company
公司概况
行业
同行对比
信号时间线
2 条日期未知
产品发布官方—
Sun Pharma Announces US Availability of UNLOXCYT (cosibelimab-ipdl)
Sun Pharma announced that UNLOXCYT (cosibelimab-ipdl) is now available in the U.S. for the treatment of advanced cutaneous squamous cell carcinoma (aCSCC).
监管与政策官方—
Sun Pharma receives DCGI approval for generic semaglutide
Sun Pharma has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide for the treatment of type 2 diabetes.
订阅 Sun Pharma 信号简报
当该公司有新信号时，立即收到通知。